Allergy Therapeutics (LON:AGY) Issues Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) released its earnings results on Monday. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Price Performance

Shares of AGY stock opened at GBX 5.63 ($0.07) on Monday. The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. Allergy Therapeutics has a 12-month low of GBX 2.65 ($0.03) and a 12-month high of GBX 8 ($0.10). The firm has a fifty day moving average of GBX 6.62 and a 200-day moving average of GBX 5.89. The firm has a market capitalization of £276.47 million, a price-to-earnings ratio of -5.42, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.